SecBot SecBot

RNXT

RenovoRx, Inc.
Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0001574094 Biotech & Drug Discovery
$1.31 +0.02 (+1.55%)
Oct 26 4:00 PM ET · prev $1.29
Market cap
$57.3M
Micro cap
Consensus
Buy
90% Buy or better · 10 analysts
Median target
$5.50
+320% · range $3.00–14.50
Next earnings
Nov 5
in 9 days · EPS est. −$0.05
1 year
+13.9%
from $1.15 · Oct 27
30 days
−15.5%
from $1.55
52-week range
$0.7330–2.52
−48% from high · low Nov 19
Avg volume 20D
429.0K
shares / day
Short interest
🔒 Subscribers only
Insider net
+$19.7K
3 buyers · 0 sellers · 12 mo
New fund stakes
0
Q2 2026 13F · 0 exits
Filing reports
11
analyzed by SecBot
SecBot read MIXED 2 reports · 90 days
Balance 0 bearish · 0 bullish · 2 neutral oldest → newest, height = score
Avg score ·High conf. 1/2 ·Next Earnings date, Nov 5, 2026
Strongest NEUTRAL RenovoRx, Inc. announced it will report its Q3 2026 results on November 5, 2026.
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersBULLISH

    3 insiders bought $19.7K at an average $0.7876. No open-market sales. Price is 66% above their cost.

  • InstitutionsBULLISH

    Q2 2026: 4 added (0 new), 1 trimmed or exited.

  • AnalystsBULLISH

    9 of 10 rate it Buy or better. Every target is above the price.

  • EstimatesRISING

    Current-quarter EPS estimate −$0.080 → −$0.050 over 90 days.

  • TrendDOWNTREND

    15% below its 50-day average.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
VANGUARD FIDUCIARY TRUST COADD240,330$235.5K
CITADEL ADVISORS LLCTRIM133,597$130.9K
NORTHERN TRUST CORPDOUBLED85,207$83.5K
JANE STREET GROUP, LLCADD46,399$45.5K
UBS Group AGDOUBLED20,820$20.4K
NORTHWESTERN MUTUAL WEALTH MANAGEMENT COADD99,460$100.5K
HRT FINANCIAL LPDOUBLED43,120$43.0K
JANE STREET GROUP, LLCADD24,137$24.4K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

10 analysts
Buy 90% rate it Buy or better
Strong Buy2Buy7Hold1Sell0Strong Sell0
12-month targets · 4 analysts

Price is below the lowest target. Median implies +320%.Targets as of Oct 27, 2026.

Recent actions
DateFirmActionRating
Aug 28, 2026Ascendiant Capital
MAINTAIN
MAINTAINBuy
Jun 1, 2026Ascendiant Capital
MAINTAIN
MAINTAINBuy

Insider ledger

Form 4
$19.7K
bought · 3 insiders
$0
sold · 0 insiders
+66.3%
vs their $0.7876 cost
DateInsiderTypeValue
Oct 1, 2026
Macfarlane K. Angela
Director
AWARD55,924 sh
Oct 1, 2026
RYAN UNA S
Director
AWARD55,924 sh
Oct 1, 2026
Spiegel Robert J.
Director
AWARD55,924 sh
Oct 1, 2026
Marton Laurence
Director
AWARD55,924 sh
Sep 10, 2026
VOLL MARK
Chief Financial Officer
AWARD80,000 sh
May 19, 2026
VOLL MARK
Chief Financial Officer
BUY$19.7K
Apr 3, 2026
Agah Ramtin
Chief Medical Officer
AWARD621,727 sh
Apr 3, 2026
VOLL MARK
Chief Financial Officer
AWARD80,000 sh

Earnings setup

Estimates
Nov 5
reports in 9 days
−$0.05
EPS estimate, this quarter
+38%
estimate change, 90 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.05-$0.07–-$0.03+33.3%$1.1M
Next Q-$0.05-$0.07–-$0.03+28.6%$1.3M
Current FY-$0.27-$0.27–-$0.27+12.9%$3.9M
Next FY-$0.12-$0.20–-$0.04+20.0%$11.4M

Short side

FINRA· Oct 15, 2026
🔒 Subscribers only
shares short
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 22, 2026 SEC
RenovoRx, Inc. announced it will report its Q3 2026 results on November 5, 2026.
PRESS-RELEASE — Impact 1/10
Oct 22, 2026 Earnings
RenovoRx to Report Third Quarter 2026 Financial Results and Business Highlights on November 5, 2026
RenovoRx to Report Third Quarter 2026 Financial Results and Business Highlights on November 5, 2026.
Oct 1, 2026 Insider
Macfarlane K. Angela was granted 55,924 shares
Director
Oct 1, 2026 Insider
RYAN UNA S was granted 55,924 shares
Director
Oct 1, 2026 Insider
Spiegel Robert J. was granted 55,924 shares
Director
Jul 29, 2026 SEC
RenovoRx, Inc. announced it will host a conference call on August 12 to discuss its Q2 2026 results.
PRESS-RELEASE — Impact 1/10
Jul 2, 2026 SEC
RenovoRx received a second 180-day extension from Nasdaq until December 28, 2026 to regain compliance with the $1.00…
8-K — Impact 6/10
Jun 30, 2026 Inst.
VANGUARD FIDUCIARY TRUST CO — ADD
240,330 shares ($235.5K)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 5, 2026
Earnings date
RNXT Q3 2026 Earnings Scheduled — 2026-11-05
Recent
Oct 22, 2026
Earnings
RenovoRx to Report Third Quarter 2026 Financial Results and Business Highlights on November 5, 2026
RenovoRx to Report Third Quarter 2026 Financial Results and Business Highlights on November 5, 2026...
Oct 1, 2026
Press release
RenovoRx Announces Peer-Reviewed Publication Highlighting the TAMP™ Platform's Potential to Improve Chemotherapeutic Delivery for Locally Advanced Pancreatic Cancer
Case Series Reports Tumor Treatment Response, Significant Tumor Marker Reduction, and Changes on Imaging After Treatment with TAMP in Patients with…
Aug 20, 2026
Listing
Listing Status: RNXT — Normal (was Deficient)
RenovoRx, Inc. - Common Stock | Nasdaq Financial Status Indicator D → N
Aug 12, 2026
Earnings
RenovoRx Reports Record Second Quarter 2026 Results, Driven by Accelerating Commercial Adoption and 61% Sequential Quarterly Revenue Growth
Increases 2026 Annual Revenue Guidance to a Range of $3.75M to $4.25M
Aug 12, 2026
Earnings date
RNXT Q2 2026 Earnings Scheduled — 2026-08-12

SecBot reports

11 filings · 6 press releases · 1 bullish · 1 bearish · 1 mixed · 8 neutral
All RNXT filing & press-release reports (17)